REMEDY : BNSSG referral pathways & Joint Formulary

BNSSG Adult Joint Formulary
Home > Formulary : Adult > Recent Decisions > 2019 >

Decisions 15th January 2019

At the meeting on the 15th January the following decisions were agreed:


New Drug Requests



Budesonide orodispersible tablets

  • Approved for treatment of eosinophilic esophagitis


  • Approved for treatment of mild to moderate ulcerative colitis


  • Approved for treatment resistant neuropathic pain as per BNSSG neuropathic pain guidelines

Taptiqom® eye drops

  • Approved for the reduction of intraocular pressure in adult patients with open angle glaucoma or ocular hypertension


Further work needed

Lidocaine plasters

  • The group agreed that further work was needed before lidocaine plasters could be added to the formulary.


Not Approved

Softacort® eye drops

  • Not approved for treatment of mild non-infectious allergic or inflammatory conjunctival diseases.


Shared Care Protocols/TLS change in status

Brivaracetam SCP

  • New SCP approved

Insulin degludec (TLS amber 3 months to amber no SCP)

  • The group agreed to change in TLS from amber 3 months to amber no SCP

Azathioprine SCP

  • New SCP approved for azathioprine for the management of autoimmune hepatitis

Tadalafil (TLS amber to blue)

  • The group agreed to change in TLS from amber to blue



  • Adalimumab biosimilars; Imraldi®, Amgevita® to be added
  • Insulin glargine biosimilars; Semglee® to be added